Patent directory · USPTO A61K / A61P
Patents matching “antagonist”
678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 9809623
α4β7 peptide monomer and dimer antagonists
granted -
US 9801938
Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
granted -
US 9790220
Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
granted -
US 9771350
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
granted -
US 9757383
Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
granted -
US 9751878
Tetrahydronaphthyridine somatostatin receptor 5 antagonists
granted -
US 9717752
Uses of antagonists of hyaluronan signaling
granted -
US 9714270
a4B7 integrin thioether peptide antagonists
granted -
US 9695195
5-HT3 receptor antagonists
granted -
US 9682957
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
granted -
US 9669069
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 9670229
5-HT3 receptor antagonists
granted -
US 9663509
8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
granted -
US 2017136004
Opioid Agonist Antagonist Combinations
granted -
US 9643961
Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities
granted -
US 9637535
IL-33 antagonists and uses thereof
granted -
US 9636400
VEGF specific fusion protein antagonist formulations
granted -
US 9631001
Peptide antagonists of the vasopressin-2 receptor
granted -
US 9624182
Compounds as lysophosphatidic acid receptor antagonists
granted -
US 9605000
Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
granted -
US 9579316
Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities
granted -
US 9580489
VEGF antagonist formulations suitable for intravitreal administration
granted -
US 9574004
Methods for treating or preventing asthma by administering an IL-4R antagonist
granted -
US 9572802
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
granted